Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Bladder-Saving Treatment Regimen Shows Promise in Patients with Bladder Cancer

June 10th 2021

A combination of treatment with bladder-saving surgical resection, Opdivo and chemotherapy yielded positive results in patients with muscle-invasive bladder cancer.

Front-line Bavencio Maintenance Improves Survival Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Bladder Cancer

June 7th 2021

The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

YouTube May Provide Misleading Information About Bladder Cancer

May 25th 2021

Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.

The Cancer Diagnosis That Seemed to Make Little Sense

May 24th 2021

A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.

News and Updates for Bladder Cancer Awareness Month

May 13th 2021

A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

FDA Panel Votes in Favor of Upholding Tecentriq’s Indication in First-Line Treatment of Bladder Cancer

May 5th 2021

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

A Cancer Research Writer Turns His Pain Into Hope For Others

April 22nd 2021

In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.

Almost 5% of Patients Undergo Incomplete Procedure to Remove Kidney and Nearby Tissue for Upper Tract Urothelial Carcinoma

April 13th 2021

Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

FDA Grants Accelerated Approval to Trodelvy for Advanced Bladder Cancer

April 13th 2021

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Adjusted-Dose Combination Therapy May Address Needs of Patients with Urothelial Carcinoma Unable to Tolerate Cisplatin Treatment

April 12th 2021

Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

Tecentriq’s Indication for Previously Treated Metastatic Bladder Cancer Pulled by FDA, Manufacturer

March 9th 2021

If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.

Why It’s Important to ‘Live Well With Your Cancer’

March 4th 2021

While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale.

As Cases of Bladder Cancer Rise, One Organization Can Help Educate and Connect Patients

February 24th 2021

To discuss the projected rise in bladder cancer cases in 2021, CURE® spoke with Bladder Cancer Advocacy Network (BCAN) co-founder Diane Zipursky-Quale, who offered some insight on why the numbers continue to rise, and provides some hope in the form of educational programs offered by her organization.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Bladder Cancer Matters Podcast Part 2: Why Bladder Cancer Patients May Need an Oncology Social Worker with Dr. Heather Goltz

February 15th 2021

In Episode 2 of the “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Heather Honoré Goltz in Part 2 of a two-part episode.

Bladder Cancer Matters Podcast: Should Bladder Cancer Patients Work with an Oncology Social Worker?

February 14th 2021

The Bladder Cancer Advocacy Network's new podcast by, for, and about the bladder cancer community, "Bladder Cancer Matters," has a new episode available.

BCAN's First "Bladder Cancer Matters" Podcast is Now Available

February 2nd 2021

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

Announcing BCAN’s 2021 Young Investigator Award

January 30th 2021

The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).

BCAN Announces 2021 Bladder Cancer Research Innovation Award

January 26th 2021

BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.

BCAN Ranked as a Top Charity with a 4-Star Ranking for Seventh Consecutive Year

January 18th 2021

The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.

BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients

January 11th 2021

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

Higher Tumor Classification and Grade for Nonmuscle-Invasive Bladder Cancer May Increase Recurrence and Progression Risk Up to Five Years

December 1st 2020

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

Immunotherapy Just After Chemo May Allow Some Patients with Bladder Cancer to Maintain Health Benefits

September 30th 2020

Patients with advanced or metastatic bladder cancer, after responding to initial treatment with chemotherapy, may preserve their health improvements by starting immunotherapy immediately.

There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment

September 30th 2020

After treatment for bladder or prostate cancer, many survivors confront permanent sexual side effects. The good news is that treatments and psychological support are available.

FDA Approves Bavencio as Frontline Maintenance Therapy in Advanced Bladder Cancer

July 1st 2020

The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.

Infigratinib Appears Active Across All Lines of Treatment in Patients With Advanced Bladder Cancer

June 16th 2020

"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.

Cabometyx-Tecentriq Combination Produces 'Encouraging Clinical Activity' in Previously Treated Bladder Cancer

June 12th 2020

At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.

Bavencio Soon After Chemotherapy Improves Survival in Patients with Advanced Bladder Cancer

May 29th 2020

The immunotherapy Bavencio improves survival when given as a maintenance treatment in patients whose advanced urothelial carcinoma did not progress on platinum-based chemotherapy.

Don't Ignore the Warning Signs of Cancer, Even During a Pandemic

May 19th 2020

Even amid stay at home orders to mitigate the spread of the coronavirus, listen to your body and speak to your healthcare professionals when you are worried about a potential for cancer.

What Patients with Bladder Cancer Can Do When COVID-19 Impacts Their Care

May 16th 2020

COVID-19 has drastically changed the landscape for patients with bladder cancer, but the new challenges are not insurmountable. CURE had the chance to interview the co-founder of the Bladder Cancer Advocacy Network to discuss these changes.